Therapy-related myelodysplasia and acute myeloid leukaemia (t-MDS/AML) are distinct disorders in the World Health Organization (WHO) classification of myeloid malignancies. Alkylating agent-related t-MDS/AML has a longer latency, and is associated with monosomies/deletions of chromosomes 5 and 7. Topoisomerase II inhibitor-related t-MDS/ AML has a shorter latency and is associated with MLL gene rearrangements. Both types are characterized by multilineage dysplasia, a preleukaemic phase and a poor prognosis. In addition, t-AML cases with well-defined cytogenetic abnormalities, including t(15;17)(q22;q21), t(8;21) (q22;q22) and inv(16)(p13q22), also occur (Rowley & Olney, 2002) . They are, however, comparable clinicopathologically and prognostically to de novo AML with similar cytogenetic abnormalities.
Aberrant promoter CpG methylation, leading to transcriptional silencing, is increasingly recognized as an important pathogenetic event in AML. The p15 gene, critically involved in cell cycle regulation, is commonly methylated in de novo AML, occurring in up to 93% of patients (Chim et al, 2001) .
In this study, we investigated a consecutive series of t-MDS/AML to define the frequency and time course of aberrant p15 methylation in this disorder.
MATERIALS AND METHODS
Patients. t-MDS/AML were diagnosed according to WHO classification criteria. Cytogenetic analyses were performed on overnight unstimulated cultures of marrow cells. Metaphases were Giemsa banded and karyotyped according to the International System for Human Cytogenetic Nomenclature.
Methylation-specific polymerase chain reaction (MSP) for aberrant p15 methylation. MSP for aberrant p15 methylation was performed on marrow DNA as described (Chim et al, 2001) . Briefly, 1 lg of genomic DNA was modified with bisulphite (CpGenome DNA modification kit; Intergen, USA), purified and subjected to MSP that detected the methylated (M) and unmethylated (U) promoter sequences. Positive and negative controls included universally methylated DNA (Intergen) and normal donor DNA respectively. The sensitivity of the method was estimated to be 10 )3 )10 )4 (Chim et al, 2001) .
RESULTS
Patients, clinicopathological features and treatment outcome Seventeen consecutive patients were studied (Table I) , five of whom have been reported briefly (Kwong et al, 1998; Au et al, 2000 Au et al, , 2001a àMedian survival 15 months in p15 methylated vs 5AE5 months in p15 unmethylated cases, P ¼ not significant. §The cytogenetic results for these patients have been reported elsewhere. Details of these reports are available upon request from the authors.
M: male; F: female; NHL: non-Hodgkin's lymphoma; FL: follicular lymphoma; MCL: mantle cell lymphoma; DLBCL: diffuse large B-cell lymphoma; HL: Hodgkin's lymphoma; CLL: chronic lymphocytic leukaemia; RA: rheumatoid arthritis; SLE: systemic lupus erythematosus; ALL: acute lymphoblastic leukaemia; APL: acute promyleocytic leukaemia; AMM: agnogenic myeloid metaplasia; Aza: azathioprine; CTX: cyclophosphamide; m-BACOD: methotrexate, bleomycin, cyclophosphamide, vincristine, dexamethasone; RT: radiotherapy; FND: fludarabine, mitoxantrone, dexamethasone; CEOP: cyclophosphamide, epirubicin, vincristine, predinisolone; MTX: methotrexate; MTZ: mitoxantrone; AutoBMT: autologous bone marrow transplantation; AlloBMT: allogeneic BMT; COPP: cyclophosphamide, vincristine, predinisolone, procarbazine; Dauno: daunorubicin; ABVD; adriamycin, bleomycin, vinblastine, dacarbazine; UKALL: UK ALL regimen; Ara-C: cytosine arabinoside; CVP: cyclophosphamide, vincristine, predinisolone; yr: years; m: months.
bone marrow transplantation (BMT). Only one patient had received radiotherapy. The median latency to t-MDS/AML was 7 years (range 3-13 years). The diagnoses included t-AML (n ¼ 5), acute promyelocytic leukaemia (APL, n ¼ 2), refractory anaemia with excess blasts-1 (RAEB-1, n ¼ 3), RAEB-2 (n ¼ 3), chronic myelomonocytic leukaemia-2 (CMML-2, n ¼ 1) and refractory cytopenia with multilineage dysplasia (RCMD, n ¼ 3). Cytogenetic analysis showed normal karyotypes in two patients, t(15;17) in two patients with APL, monosomies/deletions involving chromosomes 5q and/or 7q ()5/5q-, )7/7q-) and other complex changes in 11 patients, and trisomies involving chromosomes 8, 9 and 21 in two patients. The median survival was 8 months (1-44 months) with or without treatment. Three patients were in complete remission after receiving allogeneic BMT (two patients with t-MDS) and treatment with arsenic trioxide (one patient with APL). One patient with RCMD was alive with disease.
Aberrant p15 gene methylation
Aberrant p15 methylation was detected in 10 patients (59%) at the diagnosis of t-MDS/AML. Antecedent chemotherapy and diagnosis (t-MDS or t-AML) were unrelated to the occurrence of p15 gene methylation. Cytogenetically, the p15-unmethylated group contained all the patients with normal karyoytpes (n ¼ 2), t(15;17) (n ¼ 2), and )5/5q-in the absence of )7/7q-(n ¼ 3). However, p15 methylation was significantly associated with )7/7q-(P ¼ 0AE002). p15 methylation had no influence on the median blast percentage and survival (Table I) .
Serial analysis of p15 methylation
Only six patients had marrow samples available for testing before and/or after the diagnosis of t-MDS/AML. In three patients (patients 3, 7 and 15), aberrant p15 methylation was first detected at 26, 4 and 17 months before the diagnosis of t-MDS (7, 5AE5 and 2AE5 years after chemotherapy) respectively. In patient 3, p15 methylation was undetectable in the marrow after BMT (Fig 1) . DISCUSSION t-MDS/AML is an important long-term complication after chemotherapy/radiotherapy (Pedersen-Bjergaard et al, 2000) . Apart from karyotypic aberrations, other genetic alterations, particularly aberrant methylation leading to gene silencing, are not well defined in t-MDS/AML. Furthermore, the similarities/differences in genetic alterations in t-MDS/AML and de novo MDS/AML with similar cytogenetic changes are also largely unknown. Our results showed that p15 methylation occurred frequently in t-MDS/AML. In the comparison of t-MDS/ AML with de novo MDS/AML, there were a number of interesting observations. p15 methylation was significantly associated with )7/7q-in t-MDS/AML. Previous studies have shown that t-MDS/AML with )7/7q-generally has fewer additional cytogenetic aberrations and is often associated with mutations of the RAS gene (Pedersen-Bjergaard et al, 2002) . Our observations suggest that p15 methylation might be another step, in addition to )7/7q-, during the pathogenesis of t-MDS/AML. However, our findings were observed in a relatively small number of patients and will need to be validated in studies of larger numbers of patients with both de novo as well as t-MDS/AML.
Although the frequency of p15 methylation in t-MDS/ AML in this study was similar to de novo MDS (34-50%) (Uchida et al, 1997; Tien et al, 2001 ) and AML (54-93%) (Wong et al, 2000; Chim et al, 2001 ), pattern differences were observed. In the present study, p15 methylation was absent in both patients with t-APL, which contrasted with the high frequency of p15 methylation (73-100%) reported in de novo APL (Wong et al, 2000; Chim et al, 2001) . Furthermore, blast percentage and evolution from MDS to AML were unrelated to p15 methylation in t-MDS/AML, which was different from de novo MDS (Quesnel et al, 1998) , where an increase in blasts and leukaemic evolution were associated with p15 methylation. The reasons for these differences are not clear and In patient 15, p15 methylation was first detected at 4 months ()4 m) before t-MDS/AML was diagnosed. In patient 7, p15 methylation was detected at 17 months ()17 m) before t-MDS/ AML was diagnosed, but not at 37 months ()37 m). (C) Patients 6, 11 and 13 were negative for p15 methylation, whereas patients 4 and 10 were positive. will need to be further investigated in larger numbers of patients.
Finally, aberrant p15 methylation might precede t-MDS/ AML by several years, implying that this was an early event during disease evolution. Similar observations have not been made in de novo MDS/AML, as antecedent marrow samples are rarely available. With the high sensitivity of MSP (10 ) ), these observations suggested that examination for p15 methylation might be useful in detecting the early emergence of t-MDS/AML clones in selected high-risk patients. Further prospective studies will be required to verify whether earlier detection of t-MDS/AML may impact on treatment results and prognosis in these patients.
